This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win
by Zacks Equity Research
LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor optimism.
PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?
by Ahan Chakraborty
Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud growth and elevate execution risks.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?
by Zacks Equity Research
BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.
RHHBYNegative Net Change BMYPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
ATRC Treats First Patients Using Novel Dual-Energy PFA-RFA Platform
by Zacks Equity Research
AtriCure's first patients treated with its dual-energy PFA-RFA platform mark a key step as it moves toward a clinical trial next year.
BSXPositive Net Change ISRGNegative Net Change ATRCPositive Net Change MEDPNegative Net Change
medical medical-devices
Kymera's Eczema Drug Gets Fast Track Designation in the United States
by Zacks Equity Research
KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.
SNYPositive Net Change GILDPositive Net Change KYMRPositive Net Change
biotechnology biotechs medical pharmaceuticals
CBLL Gets FDA Consent for One-of-a-Kind Delirium Monitoring Solution
by Zacks Equity Research
CeriBell gains FDA clearance for its continuous delirium monitoring solution, boosting its AI-driven EEG platform and expanding its role in critical care.
BSXPositive Net Change ATRCPositive Net Change PAHCNegative Net Change CBLLPositive Net Change
medical medical-devices
Hims & Hers Expands Weight-Management Program to the United Kingdom
by Zacks Equity Research
HIMS expands its Weight Loss Program to the United Kingdom, bringing personalized, doctor-designed care and broader access to obesity treatments.
BSXPositive Net Change ISRGNegative Net Change MEDPNegative Net Change HIMSNegative Net Change
medical medical-devices
Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options
by Zacks Equity Research
Investors need to pay close attention to ALNY stock based on the movements in the options market lately.
ALNYNegative Net Change
medical
Here's How AMGN Benefits From FDA Nod to Uplizna in Myasthenia Gravis
by Sundeep Ganoria
AMGN gains momentum as Uplizna wins FDA approval for generalized myasthenia gravis, adding a twice-yearly dosing option in a crowded autoimmune market.
JNJPositive Net Change AMGNNegative Net Change ARGXNegative Net Change
biotechs medical pharmaceuticals
What Is Driving Hologic's Strength in the US Diagnostics Market?
by Moumi Mondal
HOLX's Diagnostics gains accelerate as U.S. molecular testing drives growth and new Panther Fusion and Genius platform approvals widen its runway.
ABTPositive Net Change RHHBYNegative Net Change HOLXPositive Net Change
medical medical-devices
Is it Apt to Retain Haemonetics Stock in Your Portfolio Now?
by Zacks Equity Research
HAE's Hospital rebound and rising NexSys PCS adoption boost growth prospects despite FX and solvency pressures.
ILMNNegative Net Change HAENegative Net Change PAHCNegative Net Change BTSGPositive Net Change
medical
Tracking the Top-Performing Russell 2000 Stocks Against the Zacks Rank
by Shaun Pruitt
Adding to the unusually strong performance of the Russell 2000 this year, these top performers may certainly serve as stocks to add to your watchlist
BETRNegative Net Change COGTPositive Net Change CELCPositive Net Change RGCPositive Net Change OPENNegative Net Change IWMNegative Net Change
artificial-intelligence biotechnology earnings finance inflation interest-rate investing medical oncology-screening pharmaceuticals real-estate
MOH, Aeroflow Team Up to Offer Virtual Diabetes Care in South Carolina
by Zacks Equity Research
Molina Healthcare partners with Aeroflow Health to expand nutrition counseling and diabetes care for the former's Commercial and Medicare members in South Carolina.
MOHPositive Net Change ADUSPositive Net Change COLLPositive Net Change MEDPNegative Net Change
medical
GSK's Risvutatug Rezetecan Gets FDA's Orphan Drug Tag in Lung Cancer
by Zacks Equity Research
GSK gains FDA Orphan Drug Designation for risvutatug rezetecan, adding momentum to its fast-advancing solid-tumor pipeline.
GSKNegative Net Change ANIPNegative Net Change CRMDPositive Net Change CSTLPositive Net Change
biotechs medical
Hims & Hers Expands Its Technology-Driven Personalized Virtual Care
by Debanjana Dey
HIMS expands its tech-driven care with new diagnostics, hormonal treatments, and a Canada launch via Livewell.
TDOCPositive Net Change HIMSNegative Net Change DOCSNegative Net Change
medical medical-devices
Roche's Breast Cancer Drug Cuts Risk of Death by 30% in Phase III
by Zacks Equity Research
RHHBY's giredestrant cuts the risk of invasive disease recurrence or death by 30% in phase III, fueling momentum for a next-generation endocrine therapy.
RHHBYNegative Net Change LLYPositive Net Change ANIPNegative Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?
by Ahan Chakraborty
LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in the development of their GLP-1 therapies.
NVOPositive Net Change LLYPositive Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Implied Volatility Surging for ANI Pharmaceuticals Stock Options
by Zacks Equity Research
Investors need to pay close attention to ANIP stock based on the movements in the options market lately.
ANIPNegative Net Change
biotechnology biotechs medical
WVE Stock Surges More Than 180% in a Week: What Is Driving This Rally?
by Zacks Equity Research
Wave Life Sciences' shares jump 183% as early INLIGHT data on weight-loss drug WVE-007 show notable visceral fat cuts and gains in lean mass.
NVOPositive Net Change LLYPositive Net Change WVENegative Net Change
biotechs medical pharmaceuticals
ISRG Gets FDA Clearance to Use da Vinci SP Robot for General Surgeries
by Zacks Equity Research
Intuitive Surgical broadens its da Vinci SP system with FDA clearance for three new surgeries, expanding its role in minimally invasive care.
ISRGNegative Net Change EDAPNegative Net Change VCYTNegative Net Change AORTNegative Net Change
medical medical-devices
Can Intuitive Surgical Weather GLP-1 Drag on Bariatric Surgery?
by Indrajit Bandyopadhyay
Intuitive Surgical grapples with a GLP-1-driven bariatric slump but leans on strong general surgery gains and rising da Vinci 5 adoption.
MDTNegative Net Change ISRGNegative Net Change TFXNegative Net Change
medical medical-devices
Reasons to Retain West Pharmaceutical Stock in Your Portfolio for Now
by Zacks Equity Research
WST leans on strong HVP demand, rising GLP-1 exposure and Annex 1 tailwinds, even as pricing and device margins weigh on near-term performance.
BSXPositive Net Change ISRGNegative Net Change WSTNegative Net Change MEDPNegative Net Change
medical medical-devices
Should You Continue to Hold EW Stock in Your Portfolio?
by Zacks Equity Research
Edwards Lifesciences leans on growth in Surgical Structural Heart, TAVR and TMTT, though macro pressures and litigation continue to weigh on margins.
EWNegative Net Change ILMNNegative Net Change PODDPositive Net Change BTSGPositive Net Change
medical medical-devices
Boston Scientific Sustains Momentum in the PFA Market: What's Next?
by Moumi Mondal
BSX builds momentum in PFA as FARAPULSE posts strong growth, and new trial results and expanded FDA labeling boost its AF treatment push.
ABTPositive Net Change BSXPositive Net Change MDTNegative Net Change
medical medical-devices
Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth
by Sundeep Ganoria
ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.
AZNNegative Net Change PFEPositive Net Change MRKPositive Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals